Offices – France
Explore all Offices
Global Reach

Apart from offering expert legal consultancy for local jurisdictions, CMS Francis Lefebvre partners up with you to effectively navigate the complexities of global business and legal environments.

Explore our reach
Insights – France
Explore all insights
About CMS – France
How can we help you ?

If you're not looking for legal advice, or you're not sure who to contact, fill in the form below and one of our teams will get back to you.

Contact us
Expertise
Insights

CMS lawyers can provide future-facing advice for your business across a variety of specialisms and industries, worldwide.

Explore topics
Offices
Global Reach

Apart from offering expert legal consultancy for local jurisdictions, CMS Francis Lefebvre partners up with you to effectively navigate the complexities of global business and legal environments.

Explore our reach
CMS France
Insights
About CMS
How can we help you ?

If you're not looking for legal advice, or you're not sure who to contact, fill in the form below and one of our teams will get back to you.

Contact us

Select your region

Press releases 27 Jun 2012 · France

CMS Bureau Francis Lefebvre advises Finesco-Scomedica

3 min read

On this page


CMS Bureau Francis Lefebvre has advised the shareholders of Finesco, the sole shareholder of Scomedica, a leading French healthcare contract sales organisation, for the contribution of their shares to Apricus Bio, an American pharmaceutical company listed on the NASDAQ market.

CMS Bureau Francis Lefebvre announced today that it advised the shareholders of Finesco-Scomedica, a leading French healthcare contract sales organisation, for the contribution of all of their outstanding shares to Apricus Biosciences Inc., an American pharmaceutical company listed on the NASDAQ market.

Under the terms of the share contribution agreement, Finesco shareholders will contribute to Apricus Bio 100% of the outstanding common stock of Finesco in exchange for newly issued shares of Apricus Bio common stock valued at €7 million (around $8.8 million). If Scomedica achieves certain revenue milestones during 2012, the Finesco shareholders could receive all of an additional issue of new shares worth up to €1.8 million (around $2.3 million) in the first quarter of 2013. Finesco and Scomedica will become wholly-owned subsidiaries of Apricus Bio.

Finesco/Scomedica advisors (France):
CMS Bureau Francis Lefebvre (Benoit Provost and Thomas Bortoli)

Finesco/Scomedica advisors (USA):
Kilpatrick Townsend & Stockton LLP (Richard Cicchillo and David Eaton)

Apricus Bio advisors (France):
Salans (Jean-Marc Grosperrin and Stéphane Jaffrain).


For more nformation, please contact: